BAJAJ FINSERV DIRECT LIMITED
Open Your FREE Demat Account Now!

Natco Pharma Ltd. Share Price

NSE
BSE

NSE : NATCOPHARM

BSE : 524816

Sector : Healthcare

N/A
indicator
1D
1M
3M
6M
1Y
5Y
empty graph

Day's Range

Day's Range

Low

₹841.70

High

₹857.90

Price Summary

Previous Close ₹851.50
Day's Range ₹841.70 - ₹857.90
Open ₹851.70
52 Week Range ₹789.00 - ₹1,226.80
Volume 5,60,388
Market Cap ₹0.02
Previous Close ₹853.50
Day's Range ₹841.50 - ₹858.25
Open ₹850.90
52 Week Range ₹789.30 - ₹1,226.10
Volume 20,856
Market Cap ₹0.02

Stocks Summary

Trade Value ( ₹ in Lacs) 4,771.70
Market Cap (₹ in Mn) 0.02
Dividend Yield(%) 0.59
Price/Earning (TTM) 10.70
TTM EPS (₹) 79.20
P/E Ratio 7.57
Book Value(₹) 1.65
PAT Margin (%) 39.54
Face Value (₹) 2.00
ROCE(%) 32.85
Trade Value ( ₹ in Lacs) 178.01
Market Cap (₹ in Mn) 0.02
Dividend Yield(%) 0.59
Price/Earning (TTM) 10.70
TTM EPS (₹) 79.20
P/E Ratio 7.57
Book Value(₹) 1.65
PAT Margin (%) 39.54
Face Value (₹) 2.00
ROCE(%) 32.85

Financials

Particulars QTR FY (₹ in Millions) Annual FY (₹ in Millions)
Net sales 11574.0 40945.0
Expenses N/A N/A
PBT 5208.0 22260.0
Operating profit 0.0 0.0
Net profit 4281.0 18504.0

Shareholding Pattern

Promoters (% Holding)

49.42%

Mutual funds (% Holding)

1.72%

Non-Institution (% Holding)

27.76%

FI/Banks/Insurance (% Holding)

3.30%

Government (% Holding)

0.00%

FII

17.37%

About Natco Pharma Ltd.

Founded 1981
Managing Director V C Nannapaneni
NSE Symbol NATCOPHARM

Peer Comparision

Stocks Name Market Cap (Cr)(₹) Market Price (₹) 52 Week Low-High (₹)
Sun Pharmaceutical Industries Ltd. 4,33,427.87 1,800.65 1,548.00 - 1,548.00
Divi's Laboratories Ltd. 1,75,425.62 6,729.00 5,636.50 - 5,636.50
Torrent Pharmaceuticals Ltd. 1,52,603.36 4,464.50 3,140.10 - 3,140.10
Apollo Hospitals Enterprise Ltd. 1,21,743.91 8,389.75 6,696.50 - 6,696.50
Cipla Ltd. 1,11,603.83 1,372.75 1,165.70 - 1,165.70
Zydus Lifesciences Ltd. 1,09,453.10 1,082.35 835.50 - 835.50
Dr. Reddy's Laboratories Ltd. 1,06,775.04 1,277.85 1,148.40 - 1,148.40
Lupin Ltd. 1,03,951.82 2,270.10 1,836.80 - 1,836.80
Max Healthcare Institute Ltd. 1,00,141.92 1,025.00 903.00 - 903.00
Mankind Pharma Ltd. 98,317.82 2,361.70 1,909.70 - 1,909.70
no-content No Records Found

Latest News

Jun
3
2026
EQUITY Posted on Jun 3rd 2026

Natco Pharma informs about press release

Natco Pharma has informed that it enclosed press release titled ‘NATCO Pharma Limited and Lupin Limited receive approval from U.S. FDA for Eribulin Mesylate Injection’.
The above information is a part of company’s filings submitted to BSE.
Read More
Mar
20
2026
EQUITY Posted on Mar 20th 2026

NATCO Pharma informs about press release

NATCO Pharma has informed that it enclosed the Press Release under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 regarding the launches Semaglutide Generic Injection Multi Dose Vials in India at the Most Affordable Price Starting from MRP INR 1,290.
The above information is a part of company’s filings submitted to BSE.
Read More
Jun
16
2026
EQUITY Posted on Jun 16th 2026

Panacea Biotec informs about newspaper publication

Panacea Biotec has informed that it enclosed newspaper copies regarding notice intimating the investors about the opening of a Special Window for Transfer and Dematerialization of physical shares, in accordance with SEBI Circular No. HO/38/13/11(2)2026-MIRSD-POD/I/3750/2026 dated January 30, 2026, published on June 16, 2026, in the newspapers: Financial Express; and Desh Sewak (Punjabi).

The above information is a part of company’s filings submitted to BSE. 

Read More
Jun
16
2026
EQUITY Posted on Jun 16th 2026

Suven Life Sciences informs about press release

Suven Life Sciences has informed that it enclosed News Release of the company titled ‘Suven Life Sciences announces successful completion and topline results of First-in-Human (FIH) Phase-1 clinical study of SUVN-I6107, a Muscarinic M1 Positive Allosteric Modulator (M1-PAM) and its advancement into Phase-2 clinical development’.
The above information is a part of company’s filings submitted to BSE. 
Read More
Jun
16
2026
EQUITY Posted on Jun 16th 2026

Neuland Laboratories informs about newspaper advertisement

Pursuant to Regulation 47 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulation, 2015, Neuland Laboratories has informed that it enclosed copies of newspaper advertisement regarding intimation of 42nd Annual General Meeting of the Company to be held through Video Conferencing (VC) facility/Other Audio Visual Means (OAVM), record date and other related information, as published in Financial Express and Nava Telangana on June 16, 2026.
The above information is a part of company’s filings submitted to BSE. 
Read More
no-content No Records Found

Sign in to Unlock Offers!

Explore Loans, Cards, Investments & Insurance

No SPAM We don't SPAM
Right Hand Side Image
STEP 1/2

Open Demat Account today!

+91

Enter mobile number

Invalid mobile number

Enter Full Name

Invalid Full Name

Verification required
close

Enter the One Time Password (OTP)

Sent to ********99

Edit Number
Enter valid OTP
Field should not be blank
You have exhausted your OTP attempts try again after 10 min

Request another in 60s

Resend OTP

secure   100% safe and secure

Frequently Asked Questions

What is the current share price of Natco Pharma Ltd. ?

The current share price of Natco Pharma Ltd. is ₹851.50 as of 2026-06-16.

The market capitalisation of Natco Pharma Ltd. is ₹15,180.46 as of 2026-06-15.

The 1-year return of Natco Pharma Ltd. is 3.90% as of 2026-06-16.

The P/E ratio of Natco Pharma Ltd. is 7.57 as of 2026-06-16.

The 52-week high and low of Natco Pharma Ltd. are ₹1,226.80 and ₹789.00, respectively, as of 2026-06-16.

The dividend yield of Natco Pharma Ltd. is 0.5899% as of2026-06-15.

You can buy Natco Pharma Ltd. shares through a registered stockbroker or trading platform. Bajaj Markets partners with trusted brokers to help you open a demat account. This is the first step to trading, making it easier to invest in your desired shares.

The Managing Director of Natco Pharma Ltd. is V C Nannapaneni.

When investing in a company’s stock, you may consider key factors such as its fundamentals, including financial health, historical performance, and growth potential. Assess the consistency of its performance, market conditions, and industry trends. Additionally, evaluate your own risk tolerance while reviewing aspects like quarterly earnings, management quality, and sector performance, for taking a well-informed decision.

You can track stock performance on online platforms through live market updates, historical charts, and news alerts. Regular analysis and stock alerts allow you to stay informed about significant price changes and events affecting the stock.

Common stock provides voting rights and the potential for dividends based on company performance, while in case of preferred stock, stockholders receive fixed dividends and have priority over common stockholders in asset distribution but generally lack voting rights.

Stock investments carry market risks, including price volatility, economic shifts, and sector-specific issues. Managing risk can involve diversifying your portfolio, setting stop-loss orders, and staying informed about market trends to make timely decisions.

Market capitalisation, or market cap, is the total value of a company’s outstanding shares and is calculated by multiplying the stock price by the total shares. It classifies companies as large-cap, mid-cap, or small-cap, reflecting their size, stability, and potential risk level in the stock market.

View More

People Also Ask

What healthcare products are offered by Natco Pharma Ltd.?

Natco develops generic and specialty drugs, with strong positions in oncology, cardiology, gastro, and CNS, plus agro‑chemicals through its crop‑health division.

Natco collaborates on licensing, contract manufacturing, and supplies hospital‑focused oncology generics and complex formulations in India and export markets.

Natco Pharma is an Indian pharmaceutical company that researches, develops, manufactures, and markets generic medicines, oncology‑focused products, active pharmaceutical ingredients (APIs), and agro‑health solutions for domestic and international markets.

NATCO is the brand and corporate name used by Natco Pharma Limited. The company does not prominently use or disclose an official expanded form of the abbreviation in its public corporate identity.

Before it became Natco Pharma Limited, the company was initially known as Natco Fine Pharmaceuticals, under which it started its operations in thepharmaceutical sector.

Among the products introduced by Natco Pharma in recent years is Pomalidomide Capsules, a generic version of the cancer drug Pomalyst, introduced in the U.S. for treating multiple myeloma.

The head office and registered office of Natco Pharma India is located in Hyderabad, Telangana, from where it manages its pharmaceutical and agro‑health operations for Indian and global markets.

Natco Pharma is famous for producing affordable generic and oncology medicines, including pioneering compulsory‑license versions of high‑cost cancer drugs that have significantly improved access to life‑saving treatments.

View More

Disclaimer

All content and research information displayed on the Site, are obtained from our partner Accord Fintech Private Limited. an authorized data feed vendor of BSE/NSE/MCX/NCDEX exchange. The data is provided on ‘As-Is’ basis and is not a live data feed but a feed with 15 minutes delay or more. Bajaj Markets does not warrant accuracy, completeness, timely availability of the information and data available on the Site. Past performance, when presented, is purely for reference purposes and is not a guarantee of similar future results.

The Services offered on the Site does not constitute investment advice in any manner whatsoever. You shall be solely responsible for any investment decisions made by placing reliance on the information provided on the Site.

Bajaj Markets partners with financial services entities for sourcing leads for services such as DEMAT accounts etc. In case you wish to avail the services, you shall be redirected to partners platform and shall be bound by the terms and conditions, privacy policy governing the said platform. 

Invalid Mobile Number

Invalid Full Name

Home
Home
ONDC_Shopping
Shopping
Loan
Loan Offers
My Accounts
My Accounts
Explore
Explore